Skip to content

A retrospective cohort study on the treatment of knee osteoarthritis combining traditional Chinese medicine with platelet-rich plasma.

A retrospective cohort study on the treatment of knee osteoarthritis combining traditional Chinese medicine with platelet-rich plasma.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025002376
Enrollment
Unknown
Registered
2025-12-06
Start date
2025-06-26
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

Treatment group:External application of Wenjing ointment plus PRP group
Control Group:Simple PRP group

Sponsors

Affiliated Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Patients who meet the diagnostic criteria for knee osteoarthritis in Western medicine and Chinese medical syndrome differentiation, with disease severity graded as I-III; 2) Patients aged between 40 and 75 years old,with no restriction on gender; 3) Patients who have signed the informed consent and have completed the treatment course; 4) Patients who have not undergone platelet-rich plasma therapy. Chinese medicine, or Western medicine-related treatments for knee osteoarthritis within the past three months.

Exclusion criteria

Exclusion criteria: 1) After ineffective treatment, patients with a critical condition should undergo or have undergone surgical treatment; 2) Those with a history of knee joint surgery; 3) Patients with incomplete follow-up data or lost to follow-up; 4) Patients with allergic constitutions and those allergic to multiple drugs; 5) Patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system, cardiovascular, cerebrovascular, or nervous system diseases; tuberculosis; vertebral deformities; malignant tumors; or mental illness; those suspected of abusing sedative-hypnotic drugs, opioid analgesics, or alcohol; patients with skin diseases or infectious diseases; and those with a history of gastric ulcers or bleeding.

Design outcomes

Primary

MeasureTime frame
K-L score;Joint Visual Analog Scale (VAS);The joint function evaluation is conducted using the WOMAC scale.;Quality of Life Assessment Scale SF-36 Score;

Countries

china

Contacts

Public ContactXu Jinhai

Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital

jinhaixu@126.com18016006692

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026